Akeso, Inc.
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or…
Company newsroom
Akeso, Inc.
1 releases